Clinical comparative study of rifapentine and rifampicin in treatment of tuberculosis
Author(s): MU Ke-li, CHEN Hong-Bing, Department of Internal Medicine, First Hospital of Zibo City, Tuberculosis Center, The 309th Hospital of Chinese People’s Liberation Army
Pages: 1007-1010
Year: 2014 Issue: 9
Journal: World Phytomedicines
Keyword: Rifapentine Capsule; Rifampicin Tablet; tuberculosis; adverse reactions;
Abstract: Objective To investigate the clinical efficacy of rifapentine in treatment of tuberculosis. Methods Patients with tuberculosis in First Hospital of Zibo City from March, 2009 to February, 2013 were randomly divided into control(61 cases) and treatment(61 cases) groups. All patients were po administered with Isoniazid Tablets(0.3 g/d), Pyrazinamide Tablets(1.5 g/d), and Ethambutol Hydrochloride Tablets(0.75 g/d). Patients in the treatment group were po administered with Rifapentine Capsule on the basic treatment, 0.6 g/time, once a week. Patients in the control group were po administered with Rifampicin Capsules(0.45 g/d). All the patients were treated continuously for 6 months. After treatment, the total clinical efficacy was observed, and sputum smear overcast, empty disappear, lesions absorption, and adverse reactions were observe. Results The efficacies in the treatment and control groups were 96.72% and 85.25%, respectively, and there was difference between the two groups(P < 0.05). After treatment for 3 and 6 months, the rates of sputum smear overcast, empty disappearing, and lesions absorption were significantly higher than those of control group, and there were differences between the two groups(P < 0.05). After treatment for 3 and 6 months, the gastrointestinal tract reaction and number of white blood cells reduced, levels of ALT and AST were significantly lower than those in the control group, and there were differences between the two groups(P < 0.05). Conclusion Rifapentine can obviously enhance the clinical curative effect in therapy of tuberculosis with less adverse reaction, which is more suitable for application.
Pages: 1007-1010
Year: 2014 Issue: 9
Journal: World Phytomedicines
Keyword: Rifapentine Capsule; Rifampicin Tablet; tuberculosis; adverse reactions;
Abstract: Objective To investigate the clinical efficacy of rifapentine in treatment of tuberculosis. Methods Patients with tuberculosis in First Hospital of Zibo City from March, 2009 to February, 2013 were randomly divided into control(61 cases) and treatment(61 cases) groups. All patients were po administered with Isoniazid Tablets(0.3 g/d), Pyrazinamide Tablets(1.5 g/d), and Ethambutol Hydrochloride Tablets(0.75 g/d). Patients in the treatment group were po administered with Rifapentine Capsule on the basic treatment, 0.6 g/time, once a week. Patients in the control group were po administered with Rifampicin Capsules(0.45 g/d). All the patients were treated continuously for 6 months. After treatment, the total clinical efficacy was observed, and sputum smear overcast, empty disappear, lesions absorption, and adverse reactions were observe. Results The efficacies in the treatment and control groups were 96.72% and 85.25%, respectively, and there was difference between the two groups(P < 0.05). After treatment for 3 and 6 months, the rates of sputum smear overcast, empty disappearing, and lesions absorption were significantly higher than those of control group, and there were differences between the two groups(P < 0.05). After treatment for 3 and 6 months, the gastrointestinal tract reaction and number of white blood cells reduced, levels of ALT and AST were significantly lower than those in the control group, and there were differences between the two groups(P < 0.05). Conclusion Rifapentine can obviously enhance the clinical curative effect in therapy of tuberculosis with less adverse reaction, which is more suitable for application.
Related Articles